Exenatide and dapagliflozin combination improves markers of liver steatosis and fibrosis in patients with type 2 diabetes

AIM: To assess the efficacy of exenatide (EXE) once weekly + dapagliflozin once daily (DAPA) versus each drug alone in reducing biomarkers of fatty liver/steatosis and fibrosis in a post hoc analysis of DURATION‐8, a 104‐week study in 695 patients with type 2 diabetes uncontrolled by metformin monot...

Descripción completa

Detalles Bibliográficos
Autores principales: Gastaldelli, Amalia, Repetto, Enrico, Guja, Cristian, Hardy, Elise, Han, Jenny, Jabbour, Serge A., Ferrannini, Ele
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064910/
https://www.ncbi.nlm.nih.gov/pubmed/31692226
http://dx.doi.org/10.1111/dom.13907

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7064910/
https://www.ncbi.nlm.nih.gov/pubmed/31692226
http://dx.doi.org/10.1111/dom.13907

Ejemplares similares